hl156a hl156a hl156a is a derivative of metformin and a potent oxphos inhibitor and ampk activating biguanide. certain types of cancer cells requires oxphos to survive. by targeting it, hl156a might help in improving anticancer therapy. it is more potent than aicar or metformin at activating ampk. it is synthesized by hanall biopharma. hl156aclinical dataother namesim156, hl271 acetate, unii-4g3buv6zskidentifiers iupac name n'-carbamimidoyl]pyrrolidine-1-carboximidamide cas number1422365-93-2pubchem cid71512108chemspider92169512unii4g3buv6zskchemical and physical dataformulac13h16f3n5omolar mass315.300 g·mol−13d model (jsmol)interactive image smiles c1ccn(c1)c(=nc(=nc2=cc=c(c=c2)oc(f)(f)f)n)n inchi inchi=1s/c13h16f3n5o/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6h,1-2,7-8h2,(h4,17,18,19,20)key:ngfuhjwvbktnoe-uhfffaoysa-n medical uses it is in phase 1 trial in patients with advanced solid tumor and lymphoma. pharmacology apart from ampk activation, it also inhibits expression and activation of igf-1, akt, mtor, and erk. research it is researched in multiple conditions like liver and renal fibrosis, cancer and drug resistance in cancer. a drug hl176out04 with similar pharmacology has been also developed.